Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr

Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore

Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause

The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo

Medix Biochemica appoints former Thermo Fisher Scientific Lonnie Shoff to its Board of Directors

Shoff brings over 30 years of international experience in in vitro diagnostics, healthcare distribution and veterinary diagnostics

Soumya Swaminathan appointed as the Principle Advisor for the National Tuberculosis Elimination Programme

Biostar Pharma gets FDA clearance of the IND application for a Phase 2 study of Utidelone Injection

Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux

Ligand to acquire Apeiron Biologics for US$100 million

Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.

Dabur India updates on Q1 FY25

Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25

CCRAS hosts national consultative meet on traditional medicine

Signs MoUs with Shri Krishna Ayush University and Dabur India

Imfinzi improved event-free survival and overall survival for bladder cancer

First immunotherapy regimen before and after surgery to extend survival in bladder cancer

MediPharm Labs acquires advanced medical cannabis delivery method technology from Remidose Aerosols

Transaction is non-dilutive, with 100% performance-based payment through a royalty model